0000313143-25-000058 | 10-Q | XBRL Viewer

CAPITAL STOCK

3 Months Ended

Jun. 28, 2025

Share-Based Payment Arrangement [Abstract]

15. CAPITAL STOCK

Share-Based Compensation

Compensation cost related to share-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of share-based compensation expense, which is recorded on a straight line basis, is as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Selling, general and administrative expenses	$	8,034	$	6,413
Research and development	674		827
Cost of goods sold	604		388
	$	9,312	$	7,628

Stock Options

Options are granted to purchase common stock at prices as determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options generally vest in equal installments over a four year period for employees. Options expire not more than 7 years from the date of the grant. The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience.

A summary of stock option activity for the three months ended June 28, 2025 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value

	(Dollars in Thousands, Except Share and Per Share Data)
Outstanding at March 29, 2025	993,587	$	81.75	3.5	$	2,249
Granted	221,999	$	70.29
Exercised	(13,323)	$	57.10
Forfeited/Canceled	(93,535)	$	92.30
Outstanding at June 28, 2025	1,108,728	$	78.87	4.2	$	6,580
Exercisable at June 28, 2025	651,653	$	79.67	2.9	$	4,924
Vested or expected to vest at June 28, 2025	982,146	$	79.04	3.5	$	6,180

As of June 28, 2025, there was $15.4 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 3.0 years.

Restricted Stock Units

Restricted Stock Units (“RSUs”) generally vest in equal installments over a three or four period for employees and one year from grant for non-employee directors. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

A summary of RSU activity for the three months ended June 28, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 29, 2025	303,003	$	81.27
Granted	198,297	$	70.32
Vested	(137,422)	$	76.87
Forfeited	(7,802)	$	84.04
Unvested at June 28, 2025	356,076	$	76.81

As of June 28, 2025, there was $24.5 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 2.2 years.

Performance Share Units

The grant date fair value of Performance Share Units (“PSUs”), adjusted for estimated forfeitures, is recognized as expense on a straight-line basis from the grant date through the end of the performance period. The value of these PSUs is generally based on (i) relative total shareholder return (“rTSR”), which equals the total shareholder return for the Company as compared with the total shareholder return of a PSU comparison group and; (ii) the average annual organic revenue growth rate (“AAGR”) of the Company, both of which are measured over a three-year performance period. For outstanding rTSR-based PSUs, the comparison group for awards granted prior to fiscal 2026 consists of the components of the Standard and Poor’s (“S&P”) MidCap 400 Index and for awards granted in fiscal 2026 consists of the components of the S&P Health Care Equipment Select Industry Index. Depending on the Company’s performance under the above-mentioned PSU awards during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted. If the Company’s total shareholder return for the performance period is negative, then any share payout for rTSR-based PSU awards will be capped at 100% of the target award, regardless of the Company’s performance relative to the comparison group. As a result, the Company may issue up to 763,062 shares related to outstanding performance-based awards.

A summary of PSU activity for the three months ended June 28, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 29, 2025	335,843	$	112.10
Granted(1)	219,106	$	88.04
Vested(2)	(162,066)	$	84.96
Forfeited	(11,352)	$	128.54
Unvested at June 28, 2025	381,531	$	109.04

__________

(1) Includes 35,443 shares issued for awards vested during fiscal 2026 based on achievement of performance metrics.

(2) Includes the vesting of 162,066 shares that were earned for rTSR-based PSU awards granted in fiscal 2023 for performance periods ending during fiscal 2026, based on actual rTSR of 128%.

As of June 28, 2025, there was $30.0 million of total unrecognized compensation cost related to non-vested performance share units. This cost is expected to be recognized over a weighted average period of 2.3 years.

NOTES PAYABLE AND LONG-TERM DEBT

3 Months Ended

Jun. 28, 2025

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

12. NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Convertible notes, net of financing fees	$	985,182	$	983,951
Term loan, net of financing fees	238,788		240,028
Other borrowings	812		809
Total debt	1,224,782		1,224,788
Less: current portion	(303,949)		(303,558)
Long-term debt	$	920,833	$	921,230

Convertible Senior Notes

2026 Notes

On March 5, 2021, the Company issued $500.0 million aggregate principal amount of 0.0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased.

In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in interest and other income (expense), net on the condensed consolidated statements of income.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding September 1, 2025 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after June 30, 2021, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2026 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

•The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2026 Notes; or

•Prior to the related redemption date if the Company calls the 2026 Notes for redemption.

On or after September 1, 2025, until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2026 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2026 Notes is 5.7033 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $175.34 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2026 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During the first quarter of fiscal 2026, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of June 28, 2025 and were classified as short-term debt on the Company’s condensed consolidated balance sheets.

The 2026 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after March 5, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2026 Notes may require the Company to repurchase for cash all or part of their 2026 Notes at a repurchase price equal to 100% of the principal amount of the 2026 Notes to be repurchased, plus accrued and unpaid interest.

As of June 28, 2025, the $300.0 million principal balance was netted down by $1.1 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.9 million. Interest expense related to the 2026 Notes was $0.4 million for the three months ended June 28, 2025, which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.6%.

2029 Notes

On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or

•Prior to the related redemption date if the Company calls the 2029 Notes for redemption.

On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During the first quarter of fiscal 2026, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of June 28, 2025 and were classified as long-term debt on the Company’s consolidated balance sheets.

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which are amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.

As of June 28, 2025, the $700.0 million principal balance was netted down by $13.7 million of remaining debt issuance costs, resulting in a net convertible note payable of $686.3 million. Interest expense related to the 2029 Notes was $5.2 million for the three months ended June 28, 2025, which includes nominal interest expense and the amortization of the debt issuance costs. The nominal interest rate is 2.5% and the remaining debt issuance costs are amortized at an effective interest rate of 3.0%.

Capped Calls

In connection with the issuance of the 2026 Notes and the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The 2026 Notes Capped Calls each have an initial strike price of approximately $175.34 per share, and the 2029 Notes Capped Calls each have an initial strike price of approximately $117.12 per share, both subject to certain adjustments, which correspond to the initial conversion price of the convertible notes. The 2026 Notes Capped Calls have initial cap prices of $250.48, and the 2029 Notes Capped Calls have initial cap prices of $180.18 per share, both subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2026 Notes and 2029 Notes, with such offset subject to a cap based on the cap price. The 2026 Notes Capped Calls cover approximately 2,851,668 shares of the Company’s common stock, and the 2029 Notes Capped Calls cover approximately 5,976,929 shares of the Company’s common stock, both subject to anti-dilution adjustments. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2026 Notes and 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the Capped Calls was recorded as a reduction to additional paid-in capital in fiscal 2025 and will not be remeasured.

Credit Facilities

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extended their maturity dates through June 2025. The amended and restated credit agreement provided for a $700.0 million facility (the “2022 Revised Credit Facility”).

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facility and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facility, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0.0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.

Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, upon two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.

The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. During the three months ended June 28, 2025, the Company recognized $4.3 million of interest expense and amortization of debt issuance costs related to its credit facilities.

At June 28, 2025, $243.8 million was outstanding under the term loan with an effective interest rate of 6.4%, which was netted down by the $5.0 million of remaining debt discount, resulting in a net note payable of $238.8 million. The Company has scheduled principal payments of $6.3 million required during the 12 months following June 28, 2025. There were no outstanding borrowings under the revolving credit facilities at June 28, 2025. The Company also had $19.5 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of June 28, 2025.

The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of June 28, 2025.

The future aggregate amount of debt maturities are as follows:


	Debt Maturities
	(Dollars in Thousands)
Remainder of Fiscal 2026	$	304,754
Fiscal 2027	$	7,873
Fiscal 2028	$	12,564
Fiscal 2029	$	18,818
Fiscal 2030	$	900,073
Thereafter	$	479

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

INCOME TAXES	3 Months Ended
INCOME TAXES	Jun. 28, 2025
Income Tax Disclosure [Abstract]
INCOME TAXES	6. INCOME TAXES The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and is favorably impacted by jurisdictional mix of earnings and research credits generated. For the three months ended June 28, 2025, the Company reported income tax expense of $11.1 million, representing an effective tax rate of 24.7%. The effective tax rate for the three months ended June 28, 2025 includes $0.1 million of discrete tax expense, primarily related to stock compensation shortfalls. For the three months ended June 29, 2024, the Company reported income tax expense of $8.3 million, representing an effective tax rate of 17.9%. The effective tax rate for the three months ended June 29, 2024 includes $3.6 million of discrete tax benefit, primarily related to stock compensation windfalls. The discrete benefit also includes other items such as provision to return differences. The increase in the reported tax rate for the three months ended June 28, 2025, compared to the same period in fiscal 2025, relates primarily to the decrease in stock compensation windfall benefits. The One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. on July 4, 2025. The OBBBA legislation provides for the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, revisions to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented in future periods. We are currently assessing the impact of the OBBBA on the Company’s consolidated financial statements.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Earnings Per Share [Abstract]
Net income	$ 34,031	$ 38,373
Weighted average shares (in shares)	48,111,000	50,943,000
Diluted net effect of common stock equivalents (in shares)	242,000	621,000
Diluted weighted average shares (in shares)	48,353,000	51,564,000
Basic income (loss) per share (in dollars per share)	$ 0.71	$ 0.75
Diluted income (loss) per share (in dollars per share)	$ 0.70	$ 0.74
Anti-dilutive shares (in shares)	947,422	735,427

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

GOODWILL AND INTANGIBLE ASSETS - Maturity (Details) $ in Thousands	Jun. 28, 2025 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2026	$ 39,135
Fiscal 2027	50,236
Fiscal 2028	47,787
Fiscal 2029	46,540
Fiscal 2030	$ 45,272

EARNINGS PER SHARE (Tables)

3 Months Ended

Jun. 28, 2025

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands, Except Share Data)
Net income	$	34,031	$	38,373

Basic weighted average shares outstanding	48,111		50,943
Dilutive net effect of common stock equivalents	242		621
Diluted weighted average shares	48,353		51,564

Net income per share
Basic	$	0.71	$	0.75
Diluted	$	0.70	$	0.74

LEASES (Details)	3 Months Ended
LEASES (Details)	Jun. 28, 2025
Revenue from Contract with Customer Benchmark \| Product Concentration Risk \| Lessees
Concentration Risk [Line Items]
Concentration risk (as a percent)	2.00%

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Jun. 28, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Swaps

The Company held the following interest rate swaps as of June 28, 2025:


Hedged Item	Original Notional Amount		Notional Amount as of June 28, 2025		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets (Liabilities)

	(Dollars in Thousands)




1-month USD Term SOFR	$	109,900	$	102,289	9/27/2024	9/30/2024	4/30/2029	3.32%	$	218
1-month USD Term SOFR	109,900		100,906		9/27/2024	9/30/2024	4/30/2029	3.30%	310
Total	$	219,800	$	203,195					$	528

Accounts Receivable, Allowance for Credit Loss

The following is a roll forward of the allowance for credit losses:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Beginning balance	$	6,300	$	5,695
Credit loss	521		37
Recoveries	(505)		(13)
Ending balance	$	6,316	$	5,719

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its condensed consolidated statements of income for the three months ended June 28, 2025:


Derivative Instruments	Amount of Gain (Loss) Recognized in AOCL		Amount of Gain Reclassified from AOCL into Earnings		Classification in Earnings	Amount of Gain (Loss) Excluded from Effectiveness Testing		Classification in Earnings

	(Dollars in Thousands)
Designated foreign currency hedge contracts, net of tax	$	901	$	54	Net revenues, cost of goods sold and SG&A	$	532	Interest and other (expense) income, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(5,164)	Interest and other (expense) income, net
Designated interest rate swaps, net of tax	$	(1,422)	$	2	Interest and other (expense) income, net	$	—

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of the Company’s derivative instruments as they appear in its condensed consolidated balance sheets as of June 28, 2025 and March 29, 2025:


	Classification	June 28, 2025		March 29, 2025

		(Dollars in Thousands)
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	630	$	193
Non-designated foreign currency hedge contracts	Prepaid expenses and other current assets	49		85
Designated interest rate swaps	Prepaid expenses and other current assets	1,027		1,305
Designated interest rate swaps	Other long-term assets	—		1,020
Total		$	1,706	$	2,603

Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	—	$	471
Non-designated foreign currency hedge contracts	Other current liabilities	702		25

Designated interest rate swaps	Other long-term liabilities	499		—
Total		$	1,201	$	496

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 28, 2025 and March 29, 2025.


	June 28, 2025
	Level 1		Level 2		Level 3		Total

	(Dollars in Thousands)
Assets
Money market funds	$	142,516	$	—	$	—	$	142,516
Designated foreign currency hedge contracts	—		630		—		630
Non-designated foreign currency hedge contracts	—		49		—		49
Designated interest rate swaps	—		1,027		—		1,027
Total	$	142,516	$	1,706	$	—	$	144,222

Liabilities
Designated foreign currency hedge contracts	$	—	$	—	$	—	$	—
Non-designated foreign currency hedge contracts	—		702		—		702
Designated interest rate swaps	—		499		—		499
Contingent consideration	—		—		2,185		2,185
Total	$	—	$	1,201	$	2,185	$	3,386

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value at

Valuation

Unobservable

June 28, 2025

Technique

Input

Range

(Dollars in Thousands)

Revenue-based payments

1,102

Monte Carlo Simulation Model

Discount rate

6.0%

Projected fiscal year of payments

2026 - 2028

Regulatory-based payment

—

Monte Carlo Simulation Model

Discount rate

N/A

Probability of payment

Projected fiscal year of payment

N/A

Event-based payment

1,083

Monte Carlo Simulation Model

Discount rate

6.0%

Projected fiscal year of payment

2026 - 2028

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


	Contingent Consideration
	(Dollars in Thousands)
Balance at March 29, 2025	$	2,278


Change in fair value	(93)

Balance at June 28, 2025	$	2,185

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Jun. 29, 2024
Income Tax Contingency [Line Items]
Provision for income taxes	$ 11,138	$ 8,340
Reported tax rate	24.70%	17.90%
Discrete tax benefit (expense)		$ (3,600)
Stock Compensation Windfalls
Income Tax Contingency [Line Items]
Discrete tax benefit (expense)	$ (100)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Dec. 28, 2024	Jun. 29, 2024	Mar. 29, 2025	Apr. 01, 2024
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	$ 448,854			$ 446,552
Gross Carrying Amount	779,506			762,865
Aggregate amortization expense	13,300		$ 14,500
Revision of Prior Period, Reclassification, Adjustment
Finite-Lived Intangible Assets [Line Items]
Assets held for sale		$ 6,400
Developed technology \| Attune Medical
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles					$ 96,100
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	9,559			9,588
Gross Carrying Amount	$ 16,182			$ 15,955
Trade names \| Attune Medical
Finite-Lived Intangible Assets [Line Items]
Acquired intangibles					$ 1,900

RESTRUCTURING (Tables)

3 Months Ended

Jun. 28, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following table summarizes the activity for restructuring reserves related to the 2020 Program, the portfolio rationalization initiatives and the market and regional alignment initiative for the three months ended June 28, 2025, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees:


	2020 Program		Portfolio Rationalization		Market and Regional Alignment		Total

	(Dollars in Thousands)
Balance at March 29, 2025	$	290	$	2,735	$	—	$	3,025
Costs incurred, net of reversals	(67)		(1,431)		2,764		1,266
Payments	(158)		(204)		(865)		(1,227)

Balance at June 28, 2025	$	65	$	1,100	$	1,899	$	3,064

Schedule of Restructuring and Related Costs

The following presents the net restructuring costs by line item within the Company’s accompanying unaudited condensed consolidated statements of income:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Cost of goods sold	$	(385)	$	4,366
Research and development	685		(12)
Selling, general and administrative expenses	966		268
Total	$	1,266	$	4,622

The tables below present restructuring and restructuring related costs by reportable segment:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Restructuring costs
Plasma	$	568	$	63
Blood Center	(1,020)		1,163
Hospital	576		297
Corporate	1,142		3,099
Total	$	1,266	$	4,622

Restructuring related costs
Plasma	$	9	$	175
Blood Center	—		43
Hospital	—		108
Corporate	49		2,192
Total	$	58	$	2,518

Total restructuring and restructuring related costs	$	1,324	$	7,140

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024	Mar. 29, 2025
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	$ 1,324	$ 7,140
Restructuring liability	3,064		$ 3,025
Portfolio Rationalization
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	100	2,400
Cumulative costs to date			84,700
Restructuring liability	1,100		2,735
2020 Program
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	1,500	$ 4,800
Cumulative costs to date	25,600
Restructuring liability	65		290
Market And Regional Alignment Initiative
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	2,800
Cumulative costs to date	3,400
Restructuring liability	$ 1,899		$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Inventory Disclosure [Abstract]
Raw materials	$ 115,892	$ 128,574
Work-in-process	14,900	14,956
Finished goods	229,735	221,611
Inventories, net	$ 360,527	$ 365,141

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Long Term Debt Maturity (Details) $ in Thousands	Jun. 28, 2025 USD ($)
Debt Disclosure [Abstract]
Remainder of Fiscal 2026	$ 304,754
Fiscal 2027	7,873
Fiscal 2028	12,564
Fiscal 2029	18,818
Fiscal 2030	900,073
Thereafter	$ 479

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 28, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) - USD ($)			3 Months Ended
	May 28, 2024	Apr. 30, 2024	Jun. 28, 2025	Jun. 29, 2024	Mar. 29, 2025	Jul. 26, 2022	Mar. 05, 2021
Debt Instrument [Line Items]
Gain (loss) on repurchase of debt instrument			$ 0	$ 12,600,000
Debt outstanding			1,224,782,000		$ 1,224,788,000
Proceeds from issuance of convertible notes			0	700,000,000
Capped call transaction, initial strike price (in dollars per share)	$ 117.12
Capped call transaction, initial cap price (in dollars per share)	$ 180.18
Capped call transaction, anti-dilution adjustment (in shares)	5,976,929
Purchase of capped call related to convertible notes	$ 88,200,000		0	88,200,000
Repayments of long-term debt			1,563,000	$ 1,563,000
Debt instrument, percent of principal amount due in years 1-3		2.50%
Debt instrument, percent of principal amount due in year 4		5.00%
Debt instrument, percent of principal amount due in year 5		7.50%
Consolidated total leverage ratio		4.0
Consolidated interest coverage ratio		4.5
Fiscal 2027			7,873,000
Convertible notes, net of financing fees
Debt Instrument [Line Items]
Debt outstanding			985,182,000		983,951,000
Debt instrument, convertible, conversion rate				5.7033
Debt instrument, convertible, conversion price				$ 175.34
Term loan, net of financing fees
Debt Instrument [Line Items]
Long-term debt, gross			243,800,000
Debt outstanding			$ 238,788,000		$ 240,028,000
Effective interest rate			6.40%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt outstanding			$ 0
Uncommitted Operating Lines of Credit
Debt Instrument [Line Items]
Debt outstanding			0
Maximum borrowing capacity			19,500,000
Convertible Senior Notes Due 2026 \| Convertible notes, net of financing fees
Debt Instrument [Line Items]
Face amount of debt							$ 500,000,000
Stated rate (as a percent)							0.00%
Debt Instrument, Repurchased Face Amount				$ 200,000,000
Debt Instrument, Repurchase Amount				185,500,000
Gain (loss) on extinguishment of debt, before debt issuance cost writeoff				14,500,000
Deferred debt issuance cost, writeoff				1,900,000
Gain (loss) on repurchase of debt instrument				$ (12,600,000)
Long-term debt, gross			300,000,000
Debt issuance costs, net			1,100,000
Debt outstanding			298,900,000
Interest expense, debt			$ 400,000
Effective interest rate			0.60%
Convertible Senior Notes Due 2029 \| Convertible notes, net of financing fees
Debt Instrument [Line Items]
Face amount of debt	$ 700,000,000
Stated rate (as a percent)	2.50%		2.50%
Debt issuance costs, net			$ 13,700,000
Debt outstanding			686,300,000
Interest expense, debt			$ 5,200,000
Effective interest rate	3.00%		3.00%
Proceeds from issuance of convertible notes	$ 682,800,000
Debt instrument, redemption price, percentage	130.00%			130.00%
Debt instrument, redemption price, percentage of principal amount redeemed	98.00%			98.00%
Debt instrument, redemption price, percentage of previous closing price	10.00%			10.00%
Debt instrument, convertible, conversion rate	8.5385
Debt instrument, convertible, conversion price	$ 117.12
Debt issuance costs, gross	$ 17,200,000
Convertible Senior Notes Due 2029 \| Convertible notes, net of financing fees \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	130.00%			130.00%
Convertible Senior Notes Due 2029 \| Convertible notes, net of financing fees \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%			100.00%
2022 Revised Credit Facilities \| Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt						$ 700,000,000
2024 Revised Credit Facilities \| Term loan, net of financing fees
Debt Instrument [Line Items]
Face amount of debt		$ 250,000,000
Debt issuance costs, net			$ 5,000,000.0
Repayments of long-term debt		$ 12,500,000
Fiscal 2027			6,300,000
2024 Revised Credit Facilities \| Term loan, net of financing fees \| Minimum
Debt Instrument [Line Items]
Stated rate (as a percent)		1.125%
Interest rate floor		0.00%
2024 Revised Credit Facilities \| Term loan, net of financing fees \| Maximum
Debt Instrument [Line Items]
Stated rate (as a percent)		1.75%
2024 Revised Credit Facilities \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 750,000,000
Additional debt issuance costs capitalized		$ 5,900,000
2024 Revised Credit Facilities \| Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage		0.125%
2024 Revised Credit Facilities \| Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Revolving credit facility unused fee percentage		0.25%
Revised Credit Agreement \| Unsecured Debt
Debt Instrument [Line Items]
Interest expense			$ 4,300,000
2026 Notes Capped Calls
Debt Instrument [Line Items]
Capped call transaction, initial strike price (in dollars per share)	$ 175.34
Capped call transaction, initial cap price (in dollars per share)	$ 250.48
Capped call transaction, anti-dilution adjustment (in shares)	2,851,668

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 28, 2025
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	14. COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under FASB ASC Topic 450, Contingencies, for all matters. Legal costs are expensed as incurred. During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of Haemonetics, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. The parties have agreed to postpone a claim construction hearing in the matter that was originally scheduled to take place in the first quarter of fiscal 2026. The Company believes it has valid and meritorious defenses to the complaint. The Company recorded loss contingencies related to this matter in the first and fourth quarters of fiscal 2025 and in the first quarter of fiscal 2026, which did not have a material impact on its condensed consolidated financial statements. During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S. District Court for the District of Colorado (1:25-cv-01409). The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in the Company’s NexSys PCS® with YES® technology and NexSys PCS with Persona® technology. While the Company will incur costs in the course of pursuing this claim, and the outcome of litigation is inherently uncertain, the Company believes this is a necessary and appropriate action to safeguard its innovations, protect its intellectual property, and further the growth and development of its business. On June 26, 2025, Terumo filed a motion to dismiss the Company’s complaint with prejudice claiming that the Company’s asserted patents were invalid under 35 U.S.C. section 101 for claiming non-patentable subject matter. On July 17, 2025, the Company filed an amended complaint, which added a recently issued patent. On August 4, 2025, Terumo filed an inter partes review petition with the U.S. Patent and Trademark Office, seeking to invalidate one of the asserted patents. In its petition, Terumo indicated that it intends to challenge other asserted patents through inter partes review and post-grant review proceedings.

INVENTORIES (Tables)

3 Months Ended

Jun. 28, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Raw materials	$	115,892	$	128,574
Work-in-process	14,900		14,956
Finished goods	229,735		221,611
Total	$	360,527	$	365,141

GOODWILL AND INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	3 Months Ended
	Jun. 28, 2025 USD ($)
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	$ 604,269
Currency translation	3,030
Goodwill, carrying amount, ending balance	607,299
Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	29,043
Currency translation	0
Goodwill, carrying amount, ending balance	29,043
Blood Center
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	26,967
Currency translation	240
Goodwill, carrying amount, ending balance	27,207
Hospital
Goodwill [Roll Forward]
Goodwill, carrying amount, beginning balance	548,259
Currency translation	2,790
Goodwill, carrying amount, ending balance	$ 551,049

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) $ in Thousands	3 Months Ended
	Jun. 28, 2025 USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 820,836
Other comprehensive income (loss) before reclassifications	18,787
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	55
Ending Balance	882,300
Foreign Currency
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(56,248)
Other comprehensive income (loss) before reclassifications	19,307
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Ending Balance	(36,941)
Defined Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	1,149
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Ending Balance	1,149
Net Unrealized Gain (Loss) on Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	15
Other comprehensive income (loss) before reclassifications	(520)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	55
Ending Balance	(450)
Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(55,084)
Ending Balance	$ (36,242)

- Definition

Amount after tax, before reclassification adjustments of other comprehensive income (loss).

+ References + Details

- Definition

Amount after tax of reclassification adjustments of other comprehensive income (loss).

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Mar. 29, 2025
Liabilities
Change in fair value	$ (93)
Fair Value, Recurring [Member]
Assets
Money market funds	142,516	$ 158,916
Derivative Assets	1,706	2,603
Assets fair value	144,222	161,519
Liabilities
Derivative Liabilities	1,201	496
Liabilities fair value	3,386	2,774
Fair Value, Recurring [Member] \| Level 1
Assets
Money market funds	142,516	158,916
Assets fair value	142,516	158,916
Liabilities
Liabilities fair value	0	0
Fair Value, Recurring [Member] \| Level 2
Assets
Money market funds	0	0
Assets fair value	1,706	2,603
Liabilities
Liabilities fair value	1,201	496
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	2,185	2,278
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Designated as Hedging Instrument
Assets
Derivative Assets	630	193
Liabilities
Derivative Liabilities	0	471
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets		193
Liabilities
Derivative Liabilities		471
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Not Designated as Hedging Instrument
Assets
Derivative Assets	49	85
Liabilities
Derivative Liabilities	702	25
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets		85
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument
Assets
Derivative Assets		193
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	630
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument
Assets
Derivative Assets		85
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	49
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument
Liabilities
Derivative Liabilities		471
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	0
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		25
Fair Value, Recurring [Member] \| Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	702	25
Fair Value, Recurring [Member] \| Interest Rate Swap \| Designated as Hedging Instrument
Liabilities
Derivative Liabilities	499
Fair Value, Recurring [Member] \| Interest Rate Swap \| Designated as Hedging Instrument \| Level 1
Liabilities
Derivative Liabilities	0
Fair Value, Recurring [Member] \| Interest Rate Swap \| Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	499
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Current Assets \| Not Designated as Hedging Instrument
Assets
Derivative Assets		1,305
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Current Assets \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	1,027
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Noncurrent Liabilities \| Designated as Hedging Instrument
Liabilities
Derivative Liabilities		0
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Noncurrent Liabilities \| Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	499
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Assets \| Not Designated as Hedging Instrument
Assets
Derivative Assets	1,027	2,325
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Assets \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Fair Value, Recurring [Member] \| Interest Rate Swap \| Other Assets \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	1,027	2,325
Fair Value, Recurring [Member] \| Contingent Consideration
Liabilities
Liabilities fair value	2,185	2,278
Fair Value, Recurring [Member] \| Contingent Consideration \| Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	2,185	$ 2,278
Fair Value, Recurring [Member] \| Contingent Consideration \| Fair Value, Inputs, Level 3 \| Revenue-based payment
Liabilities
Liabilities fair value	$ 1,102
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate	6.00%
Fair Value, Recurring [Member] \| Contingent Consideration \| Fair Value, Inputs, Level 3 \| Regulatory-based payment
Liabilities
Liabilities fair value	$ 0
Fair Value, Recurring [Member] \| Contingent Consideration \| Fair Value, Inputs, Level 3 \| Event-based payment
Liabilities
Liabilities fair value	$ 1,083
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate	6.00%

REVENUE	3 Months Ended
REVENUE	Jun. 28, 2025
Revenue from Contract with Customer [Abstract]
REVENUE	4. REVENUE As of June 28, 2025, the Company had $36.0 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 86% of this amount as revenue within the next twelve months and the remaining balance thereafter. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the condensed consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of June 28, 2025 and March 29, 2025, the Company had contract liabilities of $49.2 million and $43.3 million, respectively. During the three months ended June 28, 2025, the Company recognized $13.3 million of revenue that was included in the above March 29, 2025 contract liability balance. Contract liabilities are classified as other current liabilities on the condensed consolidated balance sheets. As of June 28, 2025 and March 29, 2025, the Company’s contract assets were $4.3 million and $11.6 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Income Statement [Abstract]
Net revenues	$ 321,394	$ 336,172
Cost of goods sold	129,150	161,248
Gross profit	192,244	174,924
Operating expenses:
Research and development	16,261	14,449
Selling, general and administrative	110,719	108,248
Amortization of acquired intangible assets	11,392	12,471
Total operating expenses	138,372	135,168
Operating income	53,872	39,756
Interest and other (expense) income, net	(8,703)	6,957
Income before provision for income taxes	45,169	46,713
Provision for income taxes	11,138	8,340
Net income	$ 34,031	$ 38,373
Basic income (loss) per share (in dollars per share)	$ 0.71	$ 0.75
Diluted income (loss) per share (in dollars per share)	$ 0.70	$ 0.74
Weighted average shares outstanding
Basic (in shares)	48,111	50,943
Diluted (in shares)	48,353	51,564

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Jun. 28, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill by operating segment for fiscal 2026 are as follows:


	Plasma		Blood Center		Hospital		Total

	(Dollars in Thousands)
Carrying amount as of March 29, 2025	$	29,043	$	26,967	$	548,259	$	604,269



Currency translation	—		240		2,790		3,030
Carrying amount as of June 28, 2025	$	29,043	$	27,207	$	551,049	$	607,299

Schedule of Finite-Lived Intangible Assets

The gross carrying amount of intangible assets and the related accumulated amortization as of June 28, 2025 and March 29, 2025 is as follows:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)


June 28, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	511,449	$	165,871	$	345,578	12.1
Customer contracts and related relationships	138,217		72,816		65,401		12.7
Capitalized software	93,980		77,981		15,999		6.7
Patents and other	19,678		7,361		12,317		8.5
Trade names	16,182		6,623		9,559		12.3
Total	$	779,506	$	330,652	$	448,854

Non-amortizable:
In-process software development	$	1,780


Total	$	1,780


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)

March 29, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	506,143	$	156,123	$	350,020	12.1
Customer contracts and related relationships	135,561		70,842		64,719		12.6
Capitalized software	85,528		76,185		9,343		6.9
Patents and other	19,678		6,796		12,882		8.5
Trade names	15,955		6,367		9,588		12.3
Total	$	762,865	$	316,313	$	446,552

Non-amortizable:


In-process software development	$	9,190
Total	$	9,190

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:


	Amortization Expense
	(Dollars in Thousands)
Remainder of Fiscal 2026	$	39,135
Fiscal 2027	$	50,236
Fiscal 2028	$	47,787
Fiscal 2029	$	46,540
Fiscal 2030	$	45,272

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

3 Months Ended

Jun. 28, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. During the three months ended June 28, 2025, 24.6% of the Company’s sales were generated outside the U.S. in local currencies. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Franc, Mexican Peso, Chinese Yuan, and Canadian Dollar. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of June 28, 2025 and March 29, 2025 were cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $14.2 million as of June 28, 2025 and $23.6 million as of March 29, 2025. As of June 28, 2025, a gain of $0.9 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of June 28, 2025 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $109.6 million as of June 28, 2025 and $89.6 million as of March 29, 2025.

Interest Rate Swaps

Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the condensed consolidated financial statements.

Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.

The Company held the following interest rate swaps as of June 28, 2025:


Hedged Item	Original Notional Amount		Notional Amount as of June 28, 2025		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets (Liabilities)

	(Dollars in Thousands)




1-month USD Term SOFR	$	109,900	$	102,289	9/27/2024	9/30/2024	4/30/2029	3.32%	$	218
1-month USD Term SOFR	109,900		100,906		9/27/2024	9/30/2024	4/30/2029	3.30%	310
Total	$	219,800	$	203,195					$	528

For the three months ended June 28, 2025, the Company recognized a loss on the interest rate swaps to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges of $1.4 million, net of tax, in accumulated other comprehensive loss (“AOCL”) within the condensed consolidated balance sheets.

Trade Receivables

In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers; (ii) performs ongoing credit evaluations of customers’ financial condition; (iii) monitors the payment history and aging of customers’ receivables; and (iv) monitors open orders against an individual customer’s outstanding receivable balance.

The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating services. The Company has not experienced significant customer payment defaults or identified other significant collectability concerns.

The following is a roll forward of the allowance for credit losses:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Beginning balance	$	6,300	$	5,695
Credit loss	521		37
Recoveries	(505)		(13)
Ending balance	$	6,316	$	5,719

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

•Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

•Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

•Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value of Derivative Instruments


Derivative Instruments	Amount of Gain (Loss) Recognized in AOCL		Amount of Gain Reclassified from AOCL into Earnings		Classification in Earnings	Amount of Gain (Loss) Excluded from Effectiveness Testing		Classification in Earnings

	(Dollars in Thousands)
Designated foreign currency hedge contracts, net of tax	$	901	$	54	Net revenues, cost of goods sold and SG&A	$	532	Interest and other (expense) income, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(5,164)	Interest and other (expense) income, net
Designated interest rate swaps, net of tax	$	(1,422)	$	2	Interest and other (expense) income, net	$	—

The Company did not have fair value hedges or net investment hedges outstanding as of June 28, 2025 or March 29, 2025. As of June 28, 2025, there were no material deferred taxes recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 28, 2025, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

The following tables present the fair value of the Company’s derivative instruments as they appear in its condensed consolidated balance sheets as of June 28, 2025 and March 29, 2025:


	Classification	June 28, 2025		March 29, 2025

		(Dollars in Thousands)
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	630	$	193
Non-designated foreign currency hedge contracts	Prepaid expenses and other current assets	49		85
Designated interest rate swaps	Prepaid expenses and other current assets	1,027		1,305
Designated interest rate swaps	Other long-term assets	—		1,020
Total		$	1,706	$	2,603

Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	—	$	471
Non-designated foreign currency hedge contracts	Other current liabilities	702		25

Designated interest rate swaps	Other long-term liabilities	499		—
Total		$	1,201	$	496

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 28, 2025 and March 29, 2025.


	June 28, 2025
	Level 1		Level 2		Level 3		Total

	(Dollars in Thousands)
Assets
Money market funds	$	142,516	$	—	$	—	$	142,516
Designated foreign currency hedge contracts	—		630		—		630
Non-designated foreign currency hedge contracts	—		49		—		49
Designated interest rate swaps	—		1,027		—		1,027
Total	$	142,516	$	1,706	$	—	$	144,222

Liabilities
Designated foreign currency hedge contracts	$	—	$	—	$	—	$	—
Non-designated foreign currency hedge contracts	—		702		—		702
Designated interest rate swaps	—		499		—		499
Contingent consideration	—		—		2,185		2,185
Total	$	—	$	1,201	$	2,185	$	3,386


	March 29, 2025
	Level 1		Level 2		Level 3		Total

	(Dollars in Thousands)
Assets
Money market funds	$	158,916	$	—	$	—	$	158,916
Designated foreign currency hedge contracts	—		193		—		193
Non-designated foreign currency hedge contracts	—		85		—		85
Designated interest rate swaps	—		2,325		—		2,325
Total	$	158,916	$	2,603	$	—	$	161,519

Liabilities
Designated foreign currency hedge contracts	$	—	$	471	$	—	$	471
Non-designated foreign currency hedge contracts	—		25		—		25

Contingent consideration	—		—		2,278		2,278
Total	$	—	$	496	$	2,278	$	2,774

Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value at

Valuation

Unobservable

June 28, 2025

Technique

Input

Range

(Dollars in Thousands)

Revenue-based payments

1,102

Monte Carlo Simulation Model

Discount rate

6.0%

Projected fiscal year of payments

2026 - 2028

Regulatory-based payment

—

Monte Carlo Simulation Model

Discount rate

N/A

Probability of payment

Projected fiscal year of payment

N/A

Event-based payment

1,083

Monte Carlo Simulation Model

Discount rate

6.0%

Projected fiscal year of payment

2026 - 2028

The fair value of contingent consideration associated with acquisitions was $2.2 million at June 28, 2025 and the total was included in other long-term liabilities on the condensed consolidated balance sheets.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


	Contingent Consideration
	(Dollars in Thousands)
Balance at March 29, 2025	$	2,278


Change in fair value	(93)

Balance at June 28, 2025	$	2,185

Other Fair Value Disclosures

The fair values of the 2026 Notes and 2029 Notes were $289.9 million and $695.8 million as of June 28, 2025, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

EARNINGS PER SHARE

3 Months Ended

Jun. 28, 2025

Earnings Per Share [Abstract]

EARNINGS PER SHARE

7. EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands, Except Share Data)
Net income	$	34,031	$	38,373

Basic weighted average shares outstanding	48,111		50,943
Dilutive net effect of common stock equivalents	242		621
Diluted weighted average shares	48,353		51,564

Net income per share
Basic	$	0.71	$	0.75
Diluted	$	0.70	$	0.74

Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of both the convertible senior notes. For the three months ended June 28, 2025 and June 29, 2024, weighted average shares outstanding, assuming dilution, excludes the impact of 947,422 and 735,427 anti-dilutive shares, respectively.

2022 Share Repurchase Program

In August 2022, the Board approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock, based on market conditions, through August 2025. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

In April 2025, the Company completed a $150.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Goldman Sachs & Co. in February 2025. The total number of shares repurchased under the ASR was 2,386,131 at an average price per share upon final settlement of $62.86. As of March 29, 2025, the Company had fully funded the $300.0 million authorization under the 2022 share repurchase program.

2025 Share Repurchase Program

In April 2025, the Board approved a new three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

PROPERTY, PLANT AND EQUIPMENT (Tables)

3 Months Ended

Jun. 28, 2025

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Land	$	2,145	$	1,985
Building and building improvements	109,957		105,079
Plant equipment and machinery	183,666		181,825
Office equipment and information technology	132,055		130,924
Haemonetics equipment	345,314		395,152
Construction in progress	21,961		22,229
Property, plant and equipment, at cost	795,098		837,194
Less: accumulated depreciation	(508,233)		(553,142)
Property, plant and equipment, net	$	286,865	$	284,052

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands				3 Months Ended
	Jan. 13, 2025	Apr. 01, 2024	Dec. 12, 2023	Jun. 28, 2025	Dec. 28, 2024	Jun. 29, 2024	Mar. 29, 2025
Business Acquisition [Line Items]
Payments to acquire businesses, net of cash acquired				$ 0		$ 149,151
Inventories, net				(360,527)			$ (365,141)
Property, plant and equipment, net				(286,865)			(284,052)
Prepaid expenses and other current assets				58,983			60,414
Other current liabilities				$ 145,643			148,133
Revision of Prior Period, Reclassification, Adjustment
Business Acquisition [Line Items]
Inventories, net					$ 26,400
Property, plant and equipment, net					7,800
Assets held for sale					$ 6,400
Accrued liabilities							$ 100
Disposal Group, Held-for-Sale, Not Discontinued Operations \| Whole Blood Business
Business Acquisition [Line Items]
Proceeds from divestiture	$ 43,300
Contingent consideration from divestiture	$ 22,500
Attune Medical
Business Acquisition [Line Items]
Upfront payment		$ 162,000
Payments to acquire businesses, net of cash acquired		150,500
Contingent consideration		25,300
Business combination, estimated working capital adjustment		$ 400
Attune Medical \| Selling, general and administrative expenses
Business Acquisition [Line Items]
Legal and professional fees						$ 9,800
OpSens, Inc.
Business Acquisition [Line Items]
Upfront payment			$ 254,500
Payments to acquire businesses, net of cash acquired			10,600
OpSens, Inc. \| Selling, general and administrative expenses
Business Acquisition [Line Items]
Legal and professional fees			$ 6,600

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Debt Instrument [Line Items]
Debt outstanding	$ 1,224,782	$ 1,224,788
Notes payable and current maturities of long-term debt	(303,949)	(303,558)
Long-term debt	920,833	921,230
Convertible notes, net of financing fees
Debt Instrument [Line Items]
Debt outstanding	985,182	983,951
Term loan, net of financing fees
Debt Instrument [Line Items]
Debt outstanding	238,788	240,028
Other borrowings
Debt Instrument [Line Items]
Debt outstanding	$ 812	$ 809

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

3 Months Ended

Jun. 28, 2025

Debt Disclosure [Abstract]

Schedule of Debt

Notes payable and long-term debt consisted of the following:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Convertible notes, net of financing fees	$	985,182	$	983,951
Term loan, net of financing fees	238,788		240,028
Other borrowings	812		809
Total debt	1,224,782		1,224,788
Less: current portion	(303,949)		(303,558)
Long-term debt	$	920,833	$	921,230

Schedule of Maturities of Long-Term Debt

The future aggregate amount of debt maturities are as follows:


	Debt Maturities
	(Dollars in Thousands)
Remainder of Fiscal 2026	$	304,754
Fiscal 2027	$	7,873
Fiscal 2028	$	12,564
Fiscal 2029	$	18,818
Fiscal 2030	$	900,073
Thereafter	$	479

ACCUMULATED OTHER COMPREHENSIVE LOSS

3 Months Ended

Jun. 28, 2025

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

16. ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of AOCL, net of tax, are as follows:


	Foreign Currency		Defined Benefit Plans		Net Unrealized Gain (Loss) on Derivatives		Total

	(Dollars in Thousands)
Balance as of March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
Other comprehensive income (loss) before reclassifications(1)	19,307		—		(520)		18,787
Amounts reclassified from AOCL(1)	—		—		55		55
Balance as of June 28, 2025	$	(36,941)	$	1,149	$	(450)	$	(36,242)

__________

(1) Presented net of income taxes, the amounts of which are insignificant.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Divestiture of the Whole Blood Product Line and Strategic Investments (Details) $ in Thousands, € in Millions		3 Months Ended
	Jan. 13, 2025 USD ($)	Jun. 28, 2025 USD ($)	Dec. 28, 2024 USD ($)	Jun. 29, 2024 USD ($)	Jun. 28, 2025 EUR (€)	Mar. 29, 2025 USD ($)	Mar. 29, 2025 EUR (€)
Schedule of Investments [Line Items]
Inventories, net		$ (360,527)				$ (365,141)
Property, plant and equipment, net		(286,865)				(284,052)
Payment to acquire investment		12,900		$ 12,900
Gain (loss) on investments		0		$ 0
Vivasure Medical LTD
Schedule of Investments [Line Items]
Investment		$ 68,000			€ 58.0	$ 48,700	€ 45.0
Disposal Group, Held-for-Sale, Not Discontinued Operations \| Whole Blood Business
Schedule of Investments [Line Items]
Proceeds from divestiture	$ 43,300
Contingent consideration from divestiture	22,500
Disposal Group, Not Discontinued Operations \| Whole Blood
Schedule of Investments [Line Items]
Proceeds from divestiture	$ 43,300
Revision of Prior Period, Reclassification, Adjustment
Schedule of Investments [Line Items]
Inventories, net			$ 26,400
Property, plant and equipment, net			7,800
Assets held for sale			$ 6,400

RESTRUCTURING

3 Months Ended

Jun. 28, 2025

Restructuring and Related Activities [Abstract]

RESTRUCTURING

5. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

Operational Excellence Program

In July 2019, the Board of Directors of the Company (the “Board”) approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the details of the initiatives that will comprise the 2020 Program. During fiscal 2022, the Company revised the 2020 Program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The 2020 Program is closed as of March 29, 2025. During the three months ended June 28, 2025, the Company recognized reversals of previously incurred costs of $0.1 million, as compared with $2.4 million of restructuring and restructuring related costs incurred under the 2020 Program during the three months ended June 29, 2024. Total cumulative charges under the 2020 Program were $84.7 million through March 29, 2025.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. These portfolio rationalization initiatives are closed as of March 29, 2025. During the three months ended June 28, 2025, the Company recognized reversals of previously incurred costs of $1.5 million related to the divestiture of the Whole Blood product line, as compared with $4.8 million of restructuring and restructuring related costs incurred under these initiatives during the three months ended June 29, 2024. Total cumulative charges under the portfolio rationalization initiatives are $25.6 million through June 28, 2025.

Market and Regional Alignment Initiative

In May 2025, the Board approved a new market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative. This strategic initiative is designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities. The amounts and timing of estimated costs and savings are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. Initial actions related to this initiative were approved by the Board in January 2025, resulting in restructuring related costs during the fourth quarter of fiscal 2025. During the three months ended June 28, 2025, the Company incurred $2.8 million of restructuring related costs under this initiative. Total cumulative charges under the market and regional alignment initiative are $3.4 million as of June 28, 2025.


	2020 Program		Portfolio Rationalization		Market and Regional Alignment		Total

	(Dollars in Thousands)
Balance at March 29, 2025	$	290	$	2,735	$	—	$	3,025
Costs incurred, net of reversals	(67)		(1,431)		2,764		1,266
Payments	(158)		(204)		(865)		(1,227)

Balance at June 28, 2025	$	65	$	1,100	$	1,899	$	3,064

The following presents the net restructuring costs by line item within the Company’s accompanying unaudited condensed consolidated statements of income:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Cost of goods sold	$	(385)	$	4,366
Research and development	685		(12)
Selling, general and administrative expenses	966		268
Total	$	1,266	$	4,622

As of June 28, 2025, the Company had a restructuring liability of $3.1 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs that do not constitute restructuring costs under FASB ASC Topic 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The tables below present restructuring and restructuring related costs by reportable segment:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Restructuring costs
Plasma	$	568	$	63
Blood Center	(1,020)		1,163
Hospital	576		297
Corporate	1,142		3,099
Total	$	1,266	$	4,622

Restructuring related costs
Plasma	$	9	$	175
Blood Center	—		43
Hospital	—		108
Corporate	49		2,192
Total	$	58	$	2,518

Total restructuring and restructuring related costs	$	1,324	$	7,140

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025	Sep. 23, 2022
Fair Value, Recurring [Member]
Derivative [Line Items]
Derivative Assets	$ 1,706	$ 2,603
Derivative Liabilities	1,201	496
Interest Rate Swap
Derivative [Line Items]
Notional amount	203,195		$ 219,800
Estimated Fair Value Assets (Liabilities)	528
Interest Rate Swap \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	499
Interest Rate Swap \| Level 2 \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	499
Interest Rate Swap \| Other Current Assets \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		1,305
Interest Rate Swap \| Other Current Assets \| Level 2 \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	1,027
Interest Rate Swap \| Other Noncurrent Assets \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities		1,020
Interest Rate Swap \| Other Noncurrent Assets \| Level 2 \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities	0
Interest Rate Swap, 4.08% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 102,289		109,900
Derivative fixed interest rate	3.32%
Estimated Fair Value Assets (Liabilities)	$ 218
Interest Rate Swap, 4.15% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 100,906		$ 109,900
Derivative fixed interest rate	3.30%
Estimated Fair Value Assets (Liabilities)	$ 310
Foreign Exchange Contract \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	630	193
Derivative Liabilities	0	471
Foreign Exchange Contract \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	49	85
Derivative Liabilities	702	25
Foreign Exchange Contract \| Level 2 \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		193
Derivative Liabilities		471
Foreign Exchange Contract \| Level 2 \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		85
Foreign Exchange Contract \| Other Current Assets \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		193
Foreign Exchange Contract \| Other Current Assets \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets		$ 85
Foreign Exchange Contract \| Other Current Assets \| Level 2 \| Fair Value, Recurring [Member] \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	630
Foreign Exchange Contract \| Other Current Assets \| Level 2 \| Fair Value, Recurring [Member] \| Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Assets	$ 49

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Jun. 28, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the “Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the three months ended June 28, 2025 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2026 or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended March 29, 2025. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required and none have been identified.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 6,316	$ 6,300
Intangible assets, amortization	$ 330,652	$ 316,313
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	48,158,723	48,215,899
Common stock, shares outstanding (in shares)	48,158,723	48,215,899

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Cash Flows from Operating Activities:
Net income	$ 34,031	$ 38,373
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	28,758	29,136
Amortization of fair value inventory step-up	2,436	5,239
Share-based compensation expense	9,312	7,628
Gain on repurchase of convertible senior notes, net	0	(12,600)
Gains on sales of property, plant and equipment	(243)	(14,291)
Deferred income taxes	(3,231)	(3,853)
Other non-cash operating activities	1,814	1,926
Change in operating assets and liabilities:
Change in accounts receivable	3,557	7,970
Change in inventories	3,296	(36,228)
Change in prepaid income taxes	3,346	3,223
Change in other assets and other liabilities	(17,785)	(9,839)
Change in accounts payable and accrued expenses	(47,896)	(44,105)
Net cash provided by (used in) operating activities	17,395	(27,421)
Cash Flows from Investing Activities:
Capital expenditures	(3,754)	(5,656)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(11,460)	(4,211)
Acquisitions	0	(149,151)
Proceeds from sale of property, plant and equipment	297	20,362
Other investments	(18,083)	(541)
Net cash used in investing activities	(33,000)	(139,197)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	0	700,000
Repurchase of convertible senior notes	0	(185,500)
Purchase of capped call related to convertible notes	0	(88,200)
Term loan borrowings	0	250,000
Term loan redemption	0	(262,500)
Payments on revolving facility	0	50,000
Repayment of term loan borrowings	(1,563)	(1,563)
Debt issuance costs	0	(23,135)
Proceeds from employee stock purchase plan	3,476	3,441
Proceeds from exercise of stock options	462	961
Cash used to net share settle employee equity awards	(4,781)	(9,750)
Other financing activities	(36)	(62)
Net cash (used in) provided by financing activities	(2,442)	333,692
Effect of exchange rates on cash and cash equivalents	4,182	(1,445)
Net Change in Cash and Cash Equivalents	(13,865)	165,629
Cash and Cash Equivalents at Beginning of Period	306,763	178,800
Cash and Cash Equivalents at End of Period	$ 292,898	$ 344,429

CAPITAL STOCK - Schedule of Stock-Based Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 9,312	$ 7,628
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	8,034	6,413
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	674	827
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 604	$ 388

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

CAPITAL STOCK - Schedule of Summary of Equity Awards Other Than Options Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 28, 2025	Apr. 02, 2022
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Beginning Balance (in shares)	303,003
Shares, Granted (in shares)	198,297
Shares, Vested (in shares)	(137,422)
Shares, Forfeited (in shares)	(7,802)
Shares, Ending Balance (in shares)	356,076
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 81.27
Weighted Average Grant Date Fair Value (in dollars per share), Granted	70.32
Weighted Average Grant Date Fair Value (in dollars per share), Vested	76.87
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	84.04
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 76.81
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Beginning Balance (in shares)	335,843
Shares, Granted (in shares)	219,106	35,443
Shares, Vested (in shares)	(162,066)
Shares, Forfeited (in shares)	(11,352)
Shares, Ending Balance (in shares)	381,531
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 112.10
Weighted Average Grant Date Fair Value (in dollars per share), Granted	88.04
Weighted Average Grant Date Fair Value (in dollars per share), Vested	84.96
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	128.54
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 109.04
Share-based Compensation Arrangement by Share-based Payment Award, Performance Target	100.00%
Performance Shares [Member] \| Share-Based Payment Arrangement, Tranche One
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Shares, Vested (in shares)	(162,066)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Performance Target	128.00%

EARNINGS PER SHARE (Share Repurchase Program) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2025	Jun. 28, 2025	Aug. 28, 2024	Aug. 31, 2022
Share Repurchase Program [Line Items]
Shares repurchased (in shares)		363,886
2022 Share Repurchase Program
Share Repurchase Program [Line Items]
Share repurchase program, period in force		3 years
Share repurchase plan, authorized amount				$ 300.0
2024 Accelerated Share Repurchase Program
Share Repurchase Program [Line Items]
Accelerated share repurchases, settlement (payment) or receipt			$ 150.0
April 2025 Share Repurchase Program
Share Repurchase Program [Line Items]
Accelerated share repurchases, settlement (payment) or receipt	$ 500.0
Shares repurchased (in shares)	2,386,131
Accelerated share repurchases, final price paid per share	$ 62.86

- Definition

Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

+ References + Details

COVER PAGE - shares	3 Months Ended
COVER PAGE - shares	Jun. 28, 2025	Aug. 01, 2025
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 28, 2025
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORPORATION
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-28
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	125 Summer Street
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	781
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,177,256

REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended
REVENUE (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation amount	$ 36,000
Contract liabilities	49,200	$ 43,300
Revenue recognized	13,300
Contract assets	$ 4,300	$ 11,600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-06-29
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation percent	86.00%
Expected timing of satisfaction	12 months

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Statement of Comprehensive Income [Abstract]
Net income	$ 34,031	$ 38,373
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax	19,307	(7,343)
Unrealized (loss) gain on cash flow hedges, net of tax	(520)	699
Reclassifications into earnings of cash flow hedge losses (gains), net of tax	55	(391)
Other comprehensive income (loss)	18,842	(7,035)
Comprehensive income	$ 52,873	$ 31,338

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

+ Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)				1 Months Ended	3 Months Ended
	Sep. 27, 2024 swap	Sep. 26, 2024 swap	Jun. 15, 2023 swap	Sep. 30, 2022 swap	Jun. 28, 2025 USD ($)	Mar. 29, 2025 USD ($)	Apr. 01, 2024 USD ($)	Sep. 23, 2022 USD ($)
Derivative [Line Items]
Debt outstanding					$ 1,224,782,000	$ 1,224,788,000
Number of Interest Rate Swaps Remaining \| swap	2
Level 2 \| Convertible Senior Notes Due 2026
Derivative [Line Items]
Convertible notes, fair value					289,900,000
Level 2 \| Convertible Senior Notes Due 2029
Derivative [Line Items]
Convertible notes, fair value					695,800,000
Term loan, net of financing fees
Derivative [Line Items]
Debt outstanding					$ 238,788,000	240,028,000
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US					24.60%
Maturity period for foreign currency contracts					1 year
Interest Rate Swap
Derivative [Line Items]
Number of interest rate swaps entered \| swap				4
Derivative, percentage of notional value of debt	80.00%
Derivative, blended fixed interest rate	3.31%
Notional amount					$ 203,195,000			$ 219,800,000
Number Of Interest Rate Swaps Terminated \| swap		2	2
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)					0
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding					14,200,000	23,600,000
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months					900,000
Designated as Hedging Instrument \| Interest Rate Swap
Derivative [Line Items]
Amount of Gain (Loss) Recognized in AOCL					1,400,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding					$ 109,600,000	$ 89,600,000
Attune Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration							$ 25,300,000

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Apr. 01, 2024	Dec. 12, 2023	Jun. 28, 2025	Mar. 29, 2025
Business Acquisition [Line Items]
Goodwill			$ 607,299	$ 604,269
Attune Medical
Business Acquisition [Line Items]
Accounts receivable	$ 3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256
Total assets acquired	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155
Total liabilities assumed	31,040
Net assets acquired	176,206
Business combination, recognized identifiable assets acquired and liabilities assumed, cash and equivalents	11,500
Attune Medical \| Developed technology
Business Acquisition [Line Items]
Acquired intangibles	$ 96,100
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	22.00%
Attune Medical \| Customer contracts and related relationships
Business Acquisition [Line Items]
Acquired intangibles	$ 7,800
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
Attune Medical \| Trade names
Business Acquisition [Line Items]
Acquired intangibles	$ 1,900
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
OpSens, Inc.
Business Acquisition [Line Items]
Accounts receivable		$ 5,960
Inventories		12,075
Prepaid expenses and other current assets		2,062
Property, plant and equipment		3,028
Intangible assets		172,000
Goodwill		79,400
Other long-term assets		4,705
Total assets acquired		279,230
Accounts payable		3,251
Accrued payroll and related costs		1,723
Other liabilities		9,746
Deferred tax liability		14,805
Other long-term liabilities		5,853
Total liabilities assumed		35,378
Net assets acquired		243,852
OpSens, Inc. \| Developed technology
Business Acquisition [Line Items]
Acquired intangibles		$ 114,900
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
OpSens, Inc. \| Customer contracts and related relationships
Business Acquisition [Line Items]
Acquired intangibles		$ 52,300
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		18.90%
OpSens, Inc. \| Trade names
Business Acquisition [Line Items]
Acquired intangibles		$ 4,800
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Jun. 28, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

11. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by operating segment for fiscal 2026 are as follows:


	Plasma		Blood Center		Hospital		Total

	(Dollars in Thousands)
Carrying amount as of March 29, 2025	$	29,043	$	26,967	$	548,259	$	604,269



Currency translation	—		240		2,790		3,030
Carrying amount as of June 28, 2025	$	29,043	$	27,207	$	551,049	$	607,299

The gross carrying amount of intangible assets and the related accumulated amortization as of June 28, 2025 and March 29, 2025 is as follows:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)


June 28, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	511,449	$	165,871	$	345,578	12.1
Customer contracts and related relationships	138,217		72,816		65,401		12.7
Capitalized software	93,980		77,981		15,999		6.7
Patents and other	19,678		7,361		12,317		8.5
Trade names	16,182		6,623		9,559		12.3
Total	$	779,506	$	330,652	$	448,854

Non-amortizable:
In-process software development	$	1,780


Total	$	1,780


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)

March 29, 2025	(Dollars in Thousands)
Amortizable:
Developed technology	$	506,143	$	156,123	$	350,020	12.1
Customer contracts and related relationships	135,561		70,842		64,719		12.6
Capitalized software	85,528		76,185		9,343		6.9
Patents and other	19,678		6,796		12,882		8.5
Trade names	15,955		6,367		9,588		12.3
Total	$	762,865	$	316,313	$	446,552

Non-amortizable:


In-process software development	$	9,190
Total	$	9,190

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names.

During the three months ended June 28, 2025 and June 29, 2024, amortization expense was $13.3 million and $14.5 million, respectively.

Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:


	Amortization Expense
	(Dollars in Thousands)
Remainder of Fiscal 2026	$	39,135
Fiscal 2027	$	50,236
Fiscal 2028	$	47,787
Fiscal 2029	$	46,540
Fiscal 2030	$	45,272

CAPITAL STOCK - Narrative (Details) $ in Millions	3 Months Ended
CAPITAL STOCK - Narrative (Details) $ in Millions	Jun. 28, 2025 USD ($) shares
Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period (in years)	7 years
Total unrecognized compensation cost	$ 15.4
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition (in years)	3 years
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 24.5
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition (in years)	2 years 2 months 12 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 30.0
Total unrecognized compensation cost related to non-vested stock options, weighted average period of recognition (in years)	2 years 3 months 18 days
Performance period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Performance Target	100.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized \| shares	763,062
Performance Shares [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Performance Target	0.00%
Performance Shares [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Performance Target	200.00%
Employees \| Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Employees \| Restricted Stock Units (RSUs) [Member] \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Employees \| Restricted Stock Units (RSUs) [Member] \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	4 years
Director \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	1 year

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCL	$ (520)	$ 699
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCL	901
Amount of Gain Reclassified from AOCL into Earnings	54
Amount of Gain (Loss) Excluded from Effectiveness Testing	532
Designated as Hedging Instrument \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCL	(1,422)
Amount of Gain Reclassified from AOCL into Earnings	2
Amount of Gain (Loss) Excluded from Effectiveness Testing	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCL	0
Amount of Gain Reclassified from AOCL into Earnings	0
Amount of Gain (Loss) Excluded from Effectiveness Testing	$ (5,164)

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 28, 2025	Jun. 29, 2024
Pay vs Performance Disclosure
Net income	$ 34,031	$ 38,373

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

PROPERTY, PLANT AND EQUIPMENT

3 Months Ended

Jun. 28, 2025

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

9. PROPERTY, PLANT AND EQUIPMENT


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Land	$	2,145	$	1,985
Building and building improvements	109,957		105,079
Plant equipment and machinery	183,666		181,825
Office equipment and information technology	132,055		130,924
Haemonetics equipment	345,314		395,152
Construction in progress	21,961		22,229
Property, plant and equipment, at cost	795,098		837,194
Less: accumulated depreciation	(508,233)		(553,142)
Property, plant and equipment, net	$	286,865	$	284,052

During the three months ended June 28, 2025 and June 29, 2024 depreciation expense was $15.4 million and $14.6 million, respectively.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 6,300	$ 5,695
Credit loss	521	37
Recoveries	(505)	(13)
Ending balance	$ 6,316	$ 5,719

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Restructuring Reserve [Roll Forward]
Balance at March 29, 2025	$ 3,025
Costs incurred, net of reversals	1,266	$ 4,622
Payments	(1,227)
Balance at June 28, 2025	3,064
2020 Program
Restructuring Reserve [Roll Forward]
Balance at March 29, 2025	290
Costs incurred, net of reversals	(67)
Payments	(158)
Balance at June 28, 2025	65
Portfolio Rationalization
Restructuring Reserve [Roll Forward]
Balance at March 29, 2025	2,735
Costs incurred, net of reversals	(1,431)
Payments	(204)
Balance at June 28, 2025	1,100
Market And Regional Alignment Initiative
Restructuring Reserve [Roll Forward]
Balance at March 29, 2025	0
Costs incurred, net of reversals	2,764
Payments	(865)
Balance at June 28, 2025	$ 1,899

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)

3 Months Ended

Jun. 28, 2025

Investments, All Other Investments [Abstract]

Schedule of Business Acquisitions, by Acquisition

The net purchase price of $176.2 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	April 1, 2024
	(Dollars in Thousands)
Accounts receivable	$	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256

Total assets acquired	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155

Total liabilities assumed	31,040
Net assets acquired	$	176,206

The net purchase price of $243.9 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


	December 12, 2023
	(Dollars in Thousands)
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	279,230
Accounts payable	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	35,378
Net assets acquired	$	243,852

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation

	(Dollars in Thousands)
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation

	(Dollars in Thousands)
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

CAPITAL STOCK - Schedule of Summary of Stock Option Activity (Details) - Share-based Payment Arrangement, Option - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 28, 2025	Mar. 29, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	993,587
Options Outstanding, (in shares), Granted	221,999
Options Outstanding, (in shares), Exercised	(13,323)
Options Outstanding, (in shares), Forfeited	(93,535)
Options Outstanding, (in shares), Ending Balance	1,108,728	993,587
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 81.75
Weighted Average Exercise Price (in dollars per share), Granted	70.29
Weighted Average Exercise Price (in dollars per share), Exercised	57.10
Weighted Average Exercise Price (in dollars per share), Forfeited	92.30
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 78.87	$ 81.75
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	4 years 2 months 12 days	3 years 6 months
Aggregate Intrinsic Value, Balance	$ 6,580	$ 2,249
Options Outstanding, (in shares), Exercisable and End of Period	651,653
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 79.67
Weighted Average Remaining Life, Exercisable at End of Period	2 years 10 months 24 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 4,924
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	982,146
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 79.04
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years 6 months
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 6,180

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Balance (in shares) at Mar. 30, 2024		50,787,859
Beginning Balance at Mar. 30, 2024	$ 959,959	$ 508	$ 634,627	$ 360,456	$ (35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		46,860
Employee stock purchase plan	3,441		3,441
Exercise of stock options (in shares)		73,270
Exercise of stock options	961	$ 1	4,703
Exercise of stock options				(3,743)
Issuance of restricted stock, net of cancellations (in shares)		280,290
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Tax withholding on employee equity awards (in shares)		(35,393)
Tax withholding on employee equity awards	(9,759)	$ 0	(1,315)	(8,444)
Purchase of capped call related to convertible notes	88,200		88,200
Share-based compensation expense	7,628		7,628
Net income	38,373			38,373
Other comprehensive income (loss)	(7,035)				(7,035)
Balance (in shares) at Jun. 29, 2024		51,152,886
Ending Balance at Jun. 29, 2024	905,368	$ 512	560,881	386,642	(42,667)
Balance (in shares) at Mar. 29, 2025		48,215,899
Beginning Balance at Mar. 29, 2025	820,836	$ 482	523,264	352,174	(55,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		64,884
Employee stock purchase plan	3,476	$ 1	3,475
Exercise of stock options (in shares)		9,141
Exercise of stock options	$ 462	$ 0	698
Exercise of stock options				(236)
Shares repurchased (in shares)	(363,886)
Shares repurchased	$ 0	$ (4)	26,051
Shares repurchased				(26,047)
Issuance of restricted stock, net of cancellations (in shares)		250,532
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Tax withholding on employee equity awards (in shares)		(17,847)
Tax withholding on employee equity awards	(4,659)	$ 0	(783)	(3,876)
Share-based compensation expense	9,312		9,312
Net income	34,031			34,031
Other comprehensive income (loss)	18,842				18,842
Balance (in shares) at Jun. 28, 2025		48,158,723
Ending Balance at Jun. 28, 2025	$ 882,300	$ 482	$ 562,014	$ 356,046	$ (36,242)

INVENTORIES

3 Months Ended

Jun. 28, 2025

Inventory Disclosure [Abstract]

INVENTORIES

8. INVENTORIES

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Raw materials	$	115,892	$	128,574
Work-in-process	14,900		14,956
Finished goods	229,735		221,611
Total	$	360,527	$	365,141

SEGMENT AND ENTERPRISE-WIDE INFORMATION

3 Months Ended

Jun. 28, 2025

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

17. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.

The Company’s reportable and operating segments are as follows:

•Plasma

•Blood Center

•Hospital

The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.

The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.

Selected information by reportable segment is presented below:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Net revenues:
Plasma	$	129,897	$	135,910
Blood Center	51,839		66,245
Hospital	139,658		134,017
Total net revenues	$	321,394	$	336,172

Significant segment expenses and operating performance:
Plasma
Cost of goods sold	$	49,917	$	65,338
Selling, general and administrative	26,198		25,130
Research and development	5,497		3,719
Plasma operating income	$	48,285	$	41,723
Blood Center
Cost of goods sold	$	25,948	$	36,180
Selling, general and administrative	13,682		15,602
Research and development	1,319		1,684
Blood Center operating income	$	10,890	$	12,779
Hospital
Cost of goods sold	$	50,216	$	48,685
Selling, general and administrative	62,323		61,190
Research and development	8,742		7,623
Hospital operating income	$	18,377	$	16,519
Corporate and unallocated expenses
Amortization of acquired intangible assets	$	(13,828)	$	(17,710)
Acquisition, integration and divestiture related costs	(2,682)		(12,323)
Restructuring and restructuring related costs	(1,324)		(7,140)
Digital transformation costs	(5,355)		(6,345)
Remeasurement of contingent consideration	93		—
Other(1)	(584)		12,253
Operating income	53,872		39,756
Interest and other (expense) income, net	(8,703)		6,957
Income before provision for income taxes	$	45,169	$	46,713

__________

(1) Comprised of litigation-related charges for the three months ended June 28, 2025. Comprised of MDR and IVDR costs, litigation-related charges, and gains on sale of property, plant and equipment for the three months ended June 29, 2024.

Net revenues by business unit are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Plasma
Plasma net revenues	$	129,897	$	135,910

Blood Center
Apheresis	51,822		49,094
Whole Blood	17		17,151
Blood Center net revenues	51,839		66,245

Hospital
Interventional Technologies	58,483		63,044
Blood Management Technologies	81,175		70,973
Hospital net revenues	139,658		134,017

Total net revenues	$	321,394	$	336,172

Depreciation and amortization, excluding impairment charges, by business unit are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Plasma	$	12,153	$	11,916
Blood Center	1,759		3,453
Hospital	14,846		13,767
Total depreciation and amortization (excluding impairment charges)	$	28,758	$	29,136

Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Plasma	$	193,740	$	189,833
Blood Center	38,412		40,337
Hospital	54,713		53,882
Total long-lived assets	$	286,865	$	284,052

Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
United States	$	213,834	$	217,212
Japan	1,228		1,250
Europe	24,177		20,024
Rest of Asia	29,828		28,705
Other	17,798		16,861
Total long-lived assets	$	286,865	$	284,052

Net revenues by operating regions are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
United States	$	242,404	$	248,902
Japan	13,648		13,705
Europe	40,882		47,225
Rest of Asia	21,648		19,783
Other	2,812		6,557
Total net revenues	$	321,394	$	336,172

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

3 Months Ended

Jun. 28, 2025

Segment Reporting [Abstract]

Selected Information by Business Segment

Selected information by reportable segment is presented below:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Net revenues:
Plasma	$	129,897	$	135,910
Blood Center	51,839		66,245
Hospital	139,658		134,017
Total net revenues	$	321,394	$	336,172

Significant segment expenses and operating performance:
Plasma
Cost of goods sold	$	49,917	$	65,338
Selling, general and administrative	26,198		25,130
Research and development	5,497		3,719
Plasma operating income	$	48,285	$	41,723
Blood Center
Cost of goods sold	$	25,948	$	36,180
Selling, general and administrative	13,682		15,602
Research and development	1,319		1,684
Blood Center operating income	$	10,890	$	12,779
Hospital
Cost of goods sold	$	50,216	$	48,685
Selling, general and administrative	62,323		61,190
Research and development	8,742		7,623
Hospital operating income	$	18,377	$	16,519
Corporate and unallocated expenses
Amortization of acquired intangible assets	$	(13,828)	$	(17,710)
Acquisition, integration and divestiture related costs	(2,682)		(12,323)
Restructuring and restructuring related costs	(1,324)		(7,140)
Digital transformation costs	(5,355)		(6,345)
Remeasurement of contingent consideration	93		—
Other(1)	(584)		12,253
Operating income	53,872		39,756
Interest and other (expense) income, net	(8,703)		6,957
Income before provision for income taxes	$	45,169	$	46,713

Schedule of Revenues by Business Unit and Geographic Regions

Net revenues by business unit are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Plasma
Plasma net revenues	$	129,897	$	135,910

Blood Center
Apheresis	51,822		49,094
Whole Blood	17		17,151
Blood Center net revenues	51,839		66,245

Hospital
Interventional Technologies	58,483		63,044
Blood Management Technologies	81,175		70,973
Hospital net revenues	139,658		134,017

Total net revenues	$	321,394	$	336,172

Depreciation and amortization, excluding impairment charges, by business unit are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Plasma	$	12,153	$	11,916
Blood Center	1,759		3,453
Hospital	14,846		13,767
Total depreciation and amortization (excluding impairment charges)	$	28,758	$	29,136

Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
Plasma	$	193,740	$	189,833
Blood Center	38,412		40,337
Hospital	54,713		53,882
Total long-lived assets	$	286,865	$	284,052

Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:


	June 28, 2025		March 29, 2025

	(Dollars in Thousands)
United States	$	213,834	$	217,212
Japan	1,228		1,250
Europe	24,177		20,024
Rest of Asia	29,828		28,705
Other	17,798		16,861
Total long-lived assets	$	286,865	$	284,052

Net revenues by operating regions are as follows:


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
United States	$	242,404	$	248,902
Japan	13,648		13,705
Europe	40,882		47,225
Rest of Asia	21,648		19,783
Other	2,812		6,557
Total net revenues	$	321,394	$	336,172

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Jun. 28, 2025
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	2. RECENT ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASC Update No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASC Update No. 2023-09 is effective for the Company’s first fiscal year beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. The Company does not expect the adoption of ASC Update No. 2023-09 to have a material impact on its financial position or results of operations. In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures. ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,266	$ 4,622
Restructuring related costs	58	2,518
Total restructuring and restructuring related costs	1,324	7,140
Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	568	63
Restructuring related costs	9	175
Blood Center
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(1,020)	1,163
Restructuring related costs	0	43
Hospital
Restructuring Cost and Reserve [Line Items]
Restructuring costs	576	297
Restructuring related costs	0	108
Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,142	3,099
Restructuring related costs	49	2,192
Cost of goods sold
Restructuring Cost and Reserve [Line Items]
Restructuring costs	(385)	4,366
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	685	(12)
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 966	$ 268

CAPITAL STOCK (Tables)

3 Months Ended

Jun. 28, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Cost


	Three Months Ended
	June 28, 2025		June 29, 2024

	(Dollars in Thousands)
Selling, general and administrative expenses	$	8,034	$	6,413
Research and development	674		827
Cost of goods sold	604		388
	$	9,312	$	7,628

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the three months ended June 28, 2025 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value

	(Dollars in Thousands, Except Share and Per Share Data)
Outstanding at March 29, 2025	993,587	$	81.75	3.5	$	2,249
Granted	221,999	$	70.29
Exercised	(13,323)	$	57.10
Forfeited/Canceled	(93,535)	$	92.30
Outstanding at June 28, 2025	1,108,728	$	78.87	4.2	$	6,580
Exercisable at June 28, 2025	651,653	$	79.67	2.9	$	4,924
Vested or expected to vest at June 28, 2025	982,146	$	79.04	3.5	$	6,180

Schedule of Summary of Restricted Stock Units Activity

A summary of RSU activity for the three months ended June 28, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 29, 2025	303,003	$	81.27
Granted	198,297	$	70.32
Vested	(137,422)	$	76.87
Forfeited	(7,802)	$	84.04
Unvested at June 28, 2025	356,076	$	76.81

Schedule of Performance Share Unit Awards

A summary of PSU activity for the three months ended June 28, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 29, 2025	335,843	$	112.10
Granted(1)	219,106	$	88.04
Vested(2)	(162,066)	$	84.96
Forfeited	(11,352)	$	128.54
Unvested at June 28, 2025	381,531	$	109.04

__________

(1) Includes 35,443 shares issued for awards vested during fiscal 2026 based on achievement of performance metrics.

(2) Includes the vesting of 162,066 shares that were earned for rTSR-based PSU awards granted in fiscal 2023 for performance periods ending during fiscal 2026, based on actual rTSR of 128%.

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 28, 2025	Jun. 29, 2024	Mar. 29, 2025
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 795,098		$ 837,194
Less: accumulated depreciation	(508,233)		(553,142)
Property, plant and equipment, net	286,865		284,052
Depreciation	15,400	$ 14,600
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	2,145		1,985
Building and building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	109,957		105,079
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	183,666		181,825
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	132,055		130,924
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	345,314		395,152
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 21,961		$ 22,229

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

3 Months Ended

Jun. 28, 2025

Investments, All Other Investments [Abstract]

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

3. ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Acquisitions

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM® proactive esophageal cooling device, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for a net purchase price of $176.2 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of $11.5 million cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the three years following completion of the acquisition, which is uncapped, and the achievement of certain other milestones. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (“ASC 805”), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.


	April 1, 2024
	(Dollars in Thousands)
Accounts receivable	$	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256

Total assets acquired	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155

Total liabilities assumed	31,040
Net assets acquired	$	176,206

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into the Company’s Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation

	(Dollars in Thousands)
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.

Acquisition-Related Costs

The Company incurred $9.8 million of acquisition-related costs during the first quarter of fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative (“SG&A”) within the condensed consolidated statements of income.

The Company’s condensed consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition has been determined to not be material to the Company’s overall financial results.

OpSens Inc.

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for a net purchase price of $243.9 million, reflecting total consideration of $254.5 million, net of $10.6 million of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for transcatheter aortic valve replacement procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve and diastolic pressure ratio to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with ASC 805, recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.


	December 12, 2023
	(Dollars in Thousands)
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	279,230
Accounts payable	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	35,378
Net assets acquired	$	243,852

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into the Company’s Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation

	(Dollars in Thousands)
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.

Acquisition-Related Costs

The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in SG&A on the condensed consolidated statements of income.

The Company’s condensed consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

Divestiture of the Whole Blood Product Line

On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico.

On January 13, 2025, the Company completed the transaction with GVS in exchange for upfront cash consideration of $43.3 million, after customary post-closing adjustments, and up to $22.5 million in contingent consideration, based on sales growth over the three years following completion of the transaction and the achievement of certain other milestones.

The assets that were derecognized in connection with the sale consisted of $26.4 million of inventory, $7.8 million of property, plant and equipment and $6.4 million of goodwill, which were previously classified as held for sale in Prepaid expenses and other current assets in the consolidated balance sheets in the third quarter of fiscal 2025.

In connection with the sale, the Company recognized a gain from the sale of the business in Interest and other expense, net in the Consolidated Statements of Income for the year ended March 29, 2025. The gain was not material and included cash receipts of $43.3 million less net assets transferred to GVS or otherwise derecognized and net of transaction costs of $0.1 million.

As part of the sale, the Company entered into a Transition Services Agreement (“TSA”) with GVS to ensure a smooth transition of business operations. Under the TSA, the Company will continue to provide certain regulatory, quality, logistical and operational support services to GVS for a maximum period of 36 months following the transaction closing to facilitate GVS's integration of the acquired business. Under the TSA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in SG&A in the condensed consolidated statements of income, which were immaterial for the three months ended June 28, 2025.

In addition to the TSA, Haemonetics and GVS entered into a Contract Manufacturing Agreement (“CMA”), under which Haemonetics will continue to manufacture certain whole blood filtration products for GVS for a maximum term of 18 months. The CMA allows GVS to gradually transition manufacturing operations while ensuring supply continuity for customers. Under the CMA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in SG&A in the condensed consolidated statements of income, which were immaterial for the three months ended June 28, 2025.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities. As of June 28, 2025, the Company has made total investments and loans in Vivasure Medical LTD (“Vivasure”) of €58.0 million, or $68.0 million, and €45.0 million, or $48.7 million, as of March 29, 2025. The investments include preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Company has made certain other strategic investments totaling $12.9 million as of both June 28, 2025 and March 29, 2025. The Company’s strategic investments are classified as other long-term assets on the Company’s condensed consolidated balance sheets and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments during the three months ended June 28, 2025 and June 29, 2024.

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

3 Months Ended

Jun. 28, 2025

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The components of AOCL, net of tax, are as follows:


	Foreign Currency		Defined Benefit Plans		Net Unrealized Gain (Loss) on Derivatives		Total

	(Dollars in Thousands)
Balance as of March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
Other comprehensive income (loss) before reclassifications(1)	19,307		—		(520)		18,787
Amounts reclassified from AOCL(1)	—		—		55		55
Balance as of June 28, 2025	$	(36,941)	$	1,149	$	(450)	$	(36,242)

__________

(1) Presented net of income taxes, the amounts of which are insignificant.

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Current assets:
Cash and cash equivalents	$ 292,898	$ 306,763
Accounts receivable, less allowance for credit losses of $6,316 at June 28, 2025 and $6,300 at March 29, 2025	200,752	202,657
Inventories, net	360,527	365,141
Prepaid expenses and other current assets	58,983	60,414
Total current assets	913,160	934,975
Property, plant and equipment, net	286,865	284,052
Intangible assets, less accumulated amortization of $330,652 at June 28, 2025 and $316,313 at March 29, 2025	450,634	455,743
Goodwill	607,299	604,269
Deferred tax asset	7,843	7,803
Other long-term assets	196,293	164,106
Total assets	2,462,094	2,450,948
Current liabilities:
Notes payable and current maturities of long-term debt	303,949	303,558
Accounts payable	46,010	66,999
Accrued payroll and related costs	35,805	59,423
Other current liabilities	145,643	148,133
Total current liabilities	531,407	578,113
Long-term debt	920,833	921,230
Deferred tax liability	59,488	62,575
Other long-term liabilities	68,066	68,194
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 48,158,723 shares at June 28, 2025 and 48,215,899 shares at March 29, 2025	482	482
Additional paid-in capital	562,014	523,264
Retained earnings	356,046	352,174
Accumulated other comprehensive loss	(36,242)
Total stockholders’ equity	882,300	820,836
Total liabilities and stockholders’ equity	$ 2,462,094	$ 2,450,948

LEASES	3 Months Ended
LEASES	Jun. 28, 2025
Leases [Abstract]
LEASES	10. LEASES Lessor Activity Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consist of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on estimated stand-alone selling prices. Operating lease revenue represents approximately two percent of the Company’s total net revenues.

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 28, 2025	Mar. 29, 2025
Amortizable:
Gross Carrying Amount	$ 779,506	$ 762,865
Accumulated Amortization	330,652	316,313
Net Carrying Amount	448,854	446,552
Non-amortizable:	1,780	9,190
In-process software development
Amortizable:
Non-amortizable:	1,780	9,190
Developed technology
Amortizable:
Gross Carrying Amount	511,449	506,143
Accumulated Amortization	165,871	156,123
Net Carrying Amount	$ 345,578	$ 350,020
Weighted Average Remaining Life (Years)	12 years 1 month 6 days	12 years 1 month 6 days
Customer contracts and related relationships
Amortizable:
Gross Carrying Amount	$ 138,217	$ 135,561
Accumulated Amortization	72,816	70,842
Net Carrying Amount	$ 65,401	$ 64,719
Weighted Average Remaining Life (Years)	12 years 8 months 12 days	12 years 7 months 6 days
Capitalized software
Amortizable:
Gross Carrying Amount	$ 93,980	$ 85,528
Accumulated Amortization	77,981	76,185
Net Carrying Amount	$ 15,999	$ 9,343
Weighted Average Remaining Life (Years)	6 years 8 months 12 days	6 years 10 months 24 days
Patents and other
Amortizable:
Gross Carrying Amount	$ 19,678	$ 19,678
Accumulated Amortization	7,361	6,796
Net Carrying Amount	$ 12,317	$ 12,882
Weighted Average Remaining Life (Years)	8 years 6 months	8 years 6 months
Trade names
Amortizable:
Gross Carrying Amount	$ 16,182	$ 15,955
Accumulated Amortization	6,623	6,367
Net Carrying Amount	$ 9,559	$ 9,588
Weighted Average Remaining Life (Years)	12 years 3 months 18 days	12 years 3 months 18 days

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended
	Jun. 28, 2025 USD ($) segment	Jun. 29, 2024 USD ($)	Mar. 29, 2025 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| segment	3
Total net revenues	$ 321,394	$ 336,172
Operating income	53,872	39,756
Cost of goods sold	129,150	161,248
Selling, general and administrative	110,719	108,248
Research and development	16,261	14,449
Amortization of acquired intangible assets	11,392	12,471
Interest and other (expense) income, net	(8,703)	6,957
Income before provision for income taxes	45,169	46,713
Net revenues	321,394	336,172
Depreciation and amortization	28,758	29,136
Total long-lived assets	286,865		$ 284,052
United States
Segment Reporting Information [Line Items]
Total net revenues	242,404	248,902
Total long-lived assets	213,834		217,212
Japan
Segment Reporting Information [Line Items]
Total net revenues	13,648	13,705
Total long-lived assets	1,228		1,250
Europe
Segment Reporting Information [Line Items]
Total net revenues	40,882	47,225
Total long-lived assets	24,177		20,024
Rest of Asia
Segment Reporting Information [Line Items]
Total net revenues	21,648	19,783
Total long-lived assets	29,828		28,705
Other
Segment Reporting Information [Line Items]
Total net revenues	2,812	6,557
Total long-lived assets	17,798		16,861
Plasma
Segment Reporting Information [Line Items]
Total net revenues	129,897	135,910
Depreciation and amortization	12,153	11,916
Total long-lived assets	193,740		189,833
Plasma \| Plasma
Segment Reporting Information [Line Items]
Net revenues	129,897	135,910
Blood Center
Segment Reporting Information [Line Items]
Total net revenues	51,839	66,245
Depreciation and amortization	1,759	3,453
Total long-lived assets	38,412		40,337
Blood Center \| Blood Center net revenues
Segment Reporting Information [Line Items]
Net revenues	51,839	66,245
Hospital
Segment Reporting Information [Line Items]
Total net revenues	139,658	134,017
Depreciation and amortization	14,846	13,767
Total long-lived assets	54,713		$ 53,882
Hospital \| Hospital net revenues
Segment Reporting Information [Line Items]
Net revenues	139,658	134,017
Apheresis \| Blood Center net revenues
Segment Reporting Information [Line Items]
Net revenues	51,822	49,094
Whole Blood \| Blood Center net revenues
Segment Reporting Information [Line Items]
Net revenues	17	17,151
Interventional Technologies \| Hospital net revenues
Segment Reporting Information [Line Items]
Net revenues	58,483	63,044
Blood Management Technologies \| Hospital net revenues
Segment Reporting Information [Line Items]
Net revenues	81,175	70,973
Operating Segments \| Plasma
Segment Reporting Information [Line Items]
Operating income	48,285	41,723
Cost of goods sold	49,917	65,338
Selling, general and administrative	26,198	25,130
Research and development	5,497	3,719
Operating Segments \| Blood Center
Segment Reporting Information [Line Items]
Operating income	10,890	12,779
Cost of goods sold	25,948	36,180
Selling, general and administrative	13,682	15,602
Research and development	1,319	1,684
Operating Segments \| Hospital
Segment Reporting Information [Line Items]
Operating income	18,377	16,519
Cost of goods sold	50,216	48,685
Selling, general and administrative	62,323	61,190
Research and development	8,742	7,623
Corporate
Segment Reporting Information [Line Items]
Operating income	53,872	39,756
Amortization of acquired intangible assets	13,828	17,710
Acquisition, integration and divestiture related costs	(2,682)	(12,323)
Restructuring and restructuring related costs	1,324	7,140
Digital transformation costs	5,355	6,345
Remeasurement of contingent consideration	93	0
Other	$ (584)	$ 12,253